MPC-4326 Clinical Trials

Therapeutic Area: HIV Infection

Phase 2 Clinical Trial

MPC-4326 is a potent small-molecule orally bioavailable first-in-class inhibitor of  HIV viral maturation.  In December 2009, Myrexis initiated a Phase 2b clinical trial of MPC-4326 in antiretroviral-treatment-experienced HIV patients.

Visit clinicaltrials.gov for more information: http://clinicaltrials.gov/ct2/show/NCT01026727